Date: 2013-10-11
Type of information: Co-promotion agreement
Compound: abiraterone acetate (Zytiga®)
Company: AstraZeneca (UK) Janssen Pharmaceuticals K.K. (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: co-promotion
Action mechanism: Abiraterone acetate, a CYP17-inhibitor, inhibits the key enzyme which modulates the production of androgens, hormones which stimulate prostate cancer cells to grow, from all sources in the body. This helps lower the level of androgens available to the prostate cancer cells, which is the goal of treatment in prostate cancer.
Disease: prostate cancer
Details: * On October 11, 2013, AstraZeneca has announced that it has entered into an agreement with Janssen Pharmaceuticals K. K. in Japan to co-promote abiraterone acetate (Zytiga®), an innovative oral therapy for the treatment of patients with prostate cancer. Currently the main treatment option available to patients in Japan is medical castration, however prostate cancer can still progress in many patients because androgens are produced in other tissues. Janssen Pharmaceuticals K.K. submitted a marketing approval application for abiraterone acetate to the Japanese Ministry of Health, Labour and Welfare in July 2013 for the treatment of prostate cancer. The product was approved in the US by the Food and Drug Administration in April 2011, and in the EU by the European Commission in September 2011 for the treatment of patients with metastatic castration-resistant prostate cancer.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
